Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Mouse His6Interleukin-6 (mHis6IL-6) #8857

No. Size Price
8857SC 10 µg ( With Carrier ) ¥2,580.00 现货查询 购买询价
8857SF 10 µg ( Carrier Free ) ¥2,580.00 现货查询 购买询价
8857 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype

Species cross-reactivity is determined by western blot.

Applications Key:

Source / Purification

Recombinant mouse His6IL-6 (mHis6IL-6) Phe25-Thr211 (Accession #NP_112445) was expressed in human 293 cells at Cell Signaling Technology.

CST公司利用重组的鼠His6IL-6 (mHis6IL-6) Phe25-Thr211 (Accession #NP_112445)在人的293细胞中表达。

Molecular Characterization

Recombinant N-terminally His6-tagged mIL-6 has a calculated MW of 24,311. DTT-reduced and non-reduced protein migrate as 31-36 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant mHis6IL-6 was verified by amino acid sequencing.

重组的mIL-6蛋白在N-末端有His6标签,其分子量据推算为24,311Da。DTT-还原 和 未还原的蛋白迁移时是作为一个31-36kDa 的多肽而转移。其在SDS-PAGE胶中的双重迁移性质与低迁移速率是由于糖基化。重组mHis6IL-6蛋白的N-末端序列通过测序得到。

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mHis6IL-6. All lots are greater than 98% pure.

6 μg 还原 (+) 和 非还原的(-) mHis6IL-6通过SDS-PAGE检测,纯度大于98%,所有批次的纯度均高于98%。

Bioactivity

The bioactivity of recombinant mIL-6 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 and 5 pg/ml.重组蛋白mIL-6的生物活性是通过B9细胞增殖实验确定的。每个lot的ED50在0.5-5 pg/ml之间。

Coomassie Gel

Coomassie Gel

The purity of recombinant mHis6IL-6 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mHis6IL-6 and staining overnight with Coomassie Blue.重组蛋白mHis6IL-6的纯度用6 µg 降解(+)和未降解(-)的蛋白走SDS-PAGE 胶来观察。考马斯亮蓝染色过夜。

Bioactivity

Bioactivity

The proliferation of B9 cells treated with increasing concentrations of mHis6IL-6 was assessed. After 48 hr treatment with mHis6IL-6, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.用逐渐递增浓度的mHis6IL-6处理B9细胞的细胞增殖实验。在mHis6IL-6中处理48小时,细胞在四唑盐中孵育并读取OD450 - OD650 的数值。

Western Blotting

Western Blotting

Western blot analysis of extracts from B9 cells, untreated or treated with increasing concentrations of mHis6IL-6 for 10 min, using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper) and Stat3 (79D7) Rabbit mAb #4904 (lower).Western免疫印迹。用Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145(上图)和Stat3 (79D7) Rabbit mAb #4904(下图)研究未经处理和用递增浓度mHis6IL-6处理10分钟的B9细胞的细胞提取液。

Bioactivity

Bioactivity

The ability of mHis6IL-6 to induce phosphorylation of Stat3 was assessed. B9 cells were treated with increasing concentrations of mHis6IL-6 for 10 min. Cells were lysed, and phospho-Stat3 was quantified using PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA Kit #7300. OD450 is shown.研究mHis6IL-6诱导Stat3磷酸化能力的实验。用递增浓度mHis6IL-6处理B9细胞10分钟,裂解细胞,磷酸化Stat3蛋白用PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA Kit #7300定量。图中所示为OD450的数值。

Endotoxin

Less than 0.01 ng endotoxin/1 μg mHis6IL-6.

内毒素含量:<0.01 ng/1 μg mHis6IL-6。

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mHis6IL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

有载体: 每微克mHis6IL-6蛋白溶解在包含 20 μg BSA的PBS(pH 7.2)溶液中,并通过 0.22 μm 滤膜冻干。

无载体:每微克mHis6IL-6蛋白溶解在PBS(pH 7.2)溶液中,并通过 0.22 μm 滤膜冻干。

Background

IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial, and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, among others. IL-6 in concert with TGF-β is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/MAPK (Erk) cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3). This IL-6/soluble IL-6Rα complex can activate the gp130 signaling pathway on cells that express gp130, but not IL-6Rα (3). Research studies have shown that IL-6 may contribute to metastatic breast cancer by increasing expression of proangiogenic VEGF (5).

IL-6是一个潜在的急性期应答的诱导因子,它由T细胞、巨噬细胞、纤维原细胞、内皮细胞和其它细胞产生(1,2)。IL-6诱导细胞增殖和分化并作用于B细胞、T细胞、胸腺细胞和其它细胞之中。IL-6与TGF-β相作用,对Th17应答的发展非常重要。IL-6与IL-6Rα结合并通过此结合诱导gp130的同型二聚化(1)。gp130的同型二聚化引起Jak/Stat级联反应和SHP2/MAPK (Erk)级联反应(1,3,4)。IL-6也能与IL-6Rα可变剪切形成与膜无关的复合体(3)。IL-6/可溶性 IL-6Rα 复合体在表达gp130的细胞上能激活gp130信号通路,但不是IL-6Rα (3)。一些研究证明IL-6可能通过增加促血管新生因子 VEGF对乳腺癌的转移有作用(5)。

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products


For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

PathScan is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0

该产品暂无评论!

我要参与评论 :

如要参与评论请先登录网站

还没有网站账户?去注册一下吧

Products

 

Applications